Lux Biosciences Closes Multi-Million Series B Venture Financing
Biotech company raises $50M; Plans for Commercial Launch of LUVENIQ
Participants in the funding included current investors in Lux Biosciences, HBM Bioventures, Novo A/S, Prospect Venture Partners and SV Life Sciences (SVLS). Lux Biosciences, Inc. is focused on the treatment of ophthalmic diseases. Its submission stage project LUVENIQ is the oral formulation of a next-generation calcineurin inhibitor; positive phase 3 data has recently been obtained for the treatment of sight-threatening non-infectious uveitis. Lux Biosciences has been collaborating with the research team at Isotechnika Pharma, who invented the molecule. Lux Biosciences also has several early stage projects based on its mixed nanomicellar ocular formulation technology, and proprietary polymer technologies for targeted delivery of molecules to the eye.